Central Pacific Bank Trust Division Boosts Position in Eli Lilly and Company (NYSE:LLY)

Central Pacific Bank Trust Division increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,486 shares of the company's stock after purchasing an additional 1,027 shares during the period. Eli Lilly and Company makes up 0.9% of Central Pacific Bank Trust Division's investment portfolio, making the stock its 15th largest holding. Central Pacific Bank Trust Division's holdings in Eli Lilly and Company were worth $6,183,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Norges Bank purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $8,407,908,000. Proficio Capital Partners LLC raised its position in Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares during the last quarter. Wellington Management Group LLP raised its position in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Capital International Investors raised its position in Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after buying an additional 1,645,222 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $1,240,653,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $15.76 during mid-day trading on Friday, reaching $738.33. The stock had a trading volume of 6,102,436 shares, compared to its average volume of 3,643,078. The firm has a 50 day moving average price of $776.85 and a two-hundred day moving average price of $799.96. The stock has a market capitalization of $699.74 billion, a P/E ratio of 63.05, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.58 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. Eli Lilly and Company's payout ratio is 48.82%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.